Intellia Therapeutics Presents Follow-Up Data From Ongoing Phase 1 Clinical Trial Of Investigational Product Nex-Z In Patients With Transthyretin Amyloidosis With Cardiomyopathy, At AHA 2025

Author: Benzinga Newsdesk | November 10, 2025 03:22pm

• One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-up
• Consistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baseline
• Longer-term safety data consistent with previously reported Phase 1 data
   

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive follow-up data from the ongoing Phase 1 clinical trial of its investigational product nexiguran ziclumeran (nex-z) in patients with transthyretin (ATTR) amyloidosis with cardiomyopathy. Results were shared today in a late-breaking oral presentation at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana.

Posted In: NTLA